Celiac disease drugs in clinical trials: what each record shows

Short answer

NIDDK describes treatment for celiac disease as a gluten-free diet1, and a 2025 review found no treatment conclusively proven as an alternative5. A trial phase shows how far a candidate has come, not that it works: FDA says Phase 2 studies are not large enough to show whether a drug will be beneficial14.

Published by Gluten Verdict · updated · 25 sources, each linked below

Reviewed by Mark Peter, Registered dietitian (RD), on

Stack of printed pages with highlighter marks on a kitchen table beside a mug

Key points

  • Gluten Intolerance Group says nothing has proven effective yet among the drugs being studied3.
  • Several celiac trials include a gluten challenge, so read the record to see what participants ate21, 25, 29.
  • A Completed status alone does not show a drug worked48, 53.
  • Each candidate below has its record, phase, status, sponsor and last update, dated to the day we read it38.

Where things stand: has any drug been proven?

NIDDK describes treatment for celiac disease as helping people follow a gluten-free diet1. Gluten Intolerance Group’s article calls a strict gluten-free diet the only known treatment, and says several companies and multiple potential drugs are being studied though nothing has proven effective yet2, 3.

A 2025 review of current and emerging treatments reaches a similar place: despite encouraging results in preclinical and clinical trials, no treatment had been conclusively proven to be an effective alternative to the gluten-free diet5.

Researchers are nonetheless studying possible new treatments7. The rest of this page is about reading what that research does and does not show, one record at a time.

This page reports what trial records and published papers say, on the dates we read them. It does not forecast which candidate will reach patients or when, and it is not advice about anyone’s care or about joining a study.

What each trial phase tells you

FDA describes clinical trials as a typical series from early, small-scale Phase 1 studies to late-stage, large-scale Phase 3 studies11. A phase says how far a candidate has come11; it is a stage of development, not a result.

The phases as FDA describes them, with FDA’s own figures
PhaseWhat FDA says about itShare of drugs FDA says move to the next phase
Phase 1Studies are closely monitored and gather information about how a drug interacts with the human body12Approximately 70%13
Phase 2Researchers give the drug to patients with the condition; a few hundred patients are typically involved, and FDA says these studies are not large enough to show whether the drug will be beneficial14Approximately 33%15
Phase 3Designed to demonstrate whether a product offers a treatment benefit to a specific population, with 300 to 3,000 participants16Approximately 25-30%17

FDA’s page is marked “Content current as of: 01/04/2018”54, so read its percentages as FDA’s published figures from that page, not a current count13, 15, 17.

FDA also says that before filing a marketing application a developer must have adequate data from two large, controlled clinical trials18. Only one row in the candidates table below is a Phase 3 record.

Control groups, placebo and the gluten challenge

Before a trial starts, its designers decide who qualifies to take part and whether there will be a control group, along with other ways to limit research bias19, 20. In the ZED1227 and latiglutenase papers below, the comparison was with placebo21, 26.

Several celiac drug trials also ask volunteers to eat gluten on purpose, under study conditions; the ZED1227 trial’s primary end point, for example, was the attenuation of gluten-induced mucosal damage21. The papers describe several versions:

  • ZED1227: adults with well-controlled celiac disease who underwent a daily gluten challenge for a 6-week treatment21.
  • Latiglutenase: patients exposed to 2 g of gluten per day for 6 weeks25.
  • AMG 714: a gluten challenge of 2 to 4 g daily during weeks 2 to 12, given to patients without severe villous atrophy at baseline29.
  • Nexvax2: a masked bolus challenge of 10 g of vital gluten, given in week 1431. The authors write that this masked bolus challenge is an alternative to an extended gluten challenge in efficacy studies33.

So a result from a challenge trial is a result about people who were eating gluten on purpose while enrolled. Before you read a headline, check the record’s interventions list: several records we read name gluten exposure there, for example “Simulated Inadvertent Gluten Exposure (SIGE)” or “SIGE”43, 38, 39.

Endpoints: what the trial measured

The table below lists the primary endpoint each paper or record names. They fall into three kinds: the gut lining on biopsy, symptom scores, and immune markers. Other records we read list further primary outcomes, such as adverse-event counts.

Primary endpoints, in the words of the paper or record
TrialPrimary endpointKind
ZED1227 (paper)Attenuation of gluten-induced mucosal damage, measured by the ratio of villus height to crypt depth21Biopsy
AMG 714 (paper)Percentage change from baseline to week 12 in villous height-to-crypt depth ratio29Biopsy
Nexvax2 (paper)Change in celiac disease patient-reported outcomes, total gastrointestinal domain31Symptoms
TAK-062 (record NCT05353985)Change in weekly Celiac Disease Symptom Diary GI symptom severity score from baseline to week 1243Symptoms
KAN-101 (record NCT06001177)Change in villous height to crypt depth after a 2-week gluten challenge, by endoscopy with biopsy45Biopsy
TAK-101 (record NCT04530123)Change in interferon-gamma spot-forming units in a gliadin-specific ELISpot assay in HLA-DQ2.5-positive participants44Immune marker

One trial can report a primary and a secondary endpoint with different P values, and the paper says which was primary. In the latiglutenase trial the primary endpoint (change in villus height to crypt depth) was -0.04 for latiglutenase against -0.35 for placebo, P = .057, while the secondary endpoint, the mean change in intraepithelial lymphocyte density, was 9.8 against 24.8 cells/mm epithelium, P = .01827. In the ZED1227 trial the confidence interval for the intraepithelial lymphocyte difference excluded zero in the highest-dose group (-9.6 cells per 100 epithelial cells, 95% CI -14.4 to -4.8) but included zero in the lowest-dose group23.

Status words on a record

ClinicalTrials.gov records carry an overall status. These are the ones we saw, and what the rows teach:

  • Recruiting: listed for ZED1227 in non-responsive celiac disease38, DONQ5239 and FB10240.
  • Active, not recruiting: listed for amlitelimab42 and TEV-5340841.
  • Completed: the AMG 714 gluten-challenge study is listed Completed48; its paper, which names that record35, reports that AMG 714 did not prevent mucosal injury due to gluten challenge53. So Completed alone does not say whether a drug worked.
  • Terminated: the record carries a reason field, such as “Due to low enrollment related to Covid.” on a latiglutenase study49.
  • Unknown status: the Nexvax2 Phase 2 record reads Unknown status with a last update posted in March 201952, yet the paper, which names that record34, describes the study as terminated and discontinued after an interim analysis32. A stale record can trail what has happened, so read the paper too.

Candidate by candidate: records read on 17 November 2026

Each row below comes from the candidate’s ClinicalTrials.gov record, read on 17 November 2026. A candidate can have several records; we list one per row, not every study of that drug. The approach column follows how a 2025 review groups the candidates it names; it does not say which approach is more likely to work.

Celiac disease drug candidates: one record each, as read on 17 November 2026
Candidate (record)ApproachPhaseStatusLead sponsorLast update posted
ZED1227 in non-responsive celiac disease38Immune-modulating6Phase 2RecruitingDr. Falk Pharma GmbH2026-04-02
DONQ52 in active celiac disease (DAISY)39Not grouped in that review’s abstract6Phase 2RecruitingChugai Pharmaceutical2026-08-14
FB102 in adults on a gluten-free diet40Not grouped in that review’s abstract6Phase 2RecruitingForte Biosciences, Inc.2025-11-18
TEV-53408 during oral gluten exposure41Not grouped in that review’s abstract6Phase 2Active, not recruitingTeva Branded Pharmaceutical Products R&D LLC2026-10-09
Amlitelimab in non-responsive celiac disease42Not grouped in that review’s abstract6Phase 2Active, not recruitingSanofi2026-08-31
TAK-062 in active celiac disease43Not grouped in that review’s abstract6Phase 2CompletedTakeda2025-08-20
TAK-101 dose-ranging44Immune tolerization6Phase 2CompletedTakeda2026-11-10
KAN-101 phase 2a45Immune tolerization6Phase 2CompletedKanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA2025-12-18
PRV-015 in non-responsive celiac disease47Not grouped in that review’s abstract6Phase 2CompletedProvention Bio, a Sanofi Company2025-10-20
AMG 714 in adults with celiac disease48Immune-modulating6Phase 2CompletedAmgen2019-12-03
Latiglutenase in symptomatic celiac disease (crossover)49Gluten-degrading enzyme6Phase 2TerminatedEntero Therapeutics2024-08-05
Larazotide acetate phase 351Intestinal permeability6Phase 3Terminated9 Meters Biopharma, Inc.2022-07-26
Nexvax2 phase 252Immune tolerization6Phase 2Unknown statusImmusanT, Inc.2019-03-19

Status and dates change. Treat every row as true on the day we read it, and open the record for today’s version.

What published results showed

Four candidates with a peer-reviewed paper reporting trial results are described here, each as one study, in the authors’ own terms. The ZED1227 paper is not the study behind the ZED1227 row above: that record’s official title describes participants experiencing symptoms despite a gluten-free diet38, while the paper’s trial enrolled adults with well-controlled celiac disease21.

ZED1227 (oral transglutaminase 2 inhibitor)

In a 6-week trial in adults with well-controlled celiac disease on a daily gluten challenge, ZED1227 at three dose levels attenuated gluten-induced duodenal mucosal injury compared with placebo; the estimated differences from placebo in the change in the villus height to crypt depth ratio were 0.44, 0.49 and 0.4821, 22. The authors call it a preliminary trial24.

Latiglutenase

In a gluten challenge phase 2 trial, 50 patients were randomized and 43 completed; the primary endpoint P value was .05727. The paper reports record NCT0358547828, not the terminated study in the table above. The authors conclude that the drug reduced gluten-induced mucosal damage and symptom severity28.

AMG 714

In a phase 2a trial with a gluten challenge, the change in the primary endpoint did not differ significantly from placebo at either dose; the authors say effects on intraepithelial lymphocytes and symptoms suggest further research may be warranted in non-responsive celiac disease30.

Nexvax2

In a phase 2 trial with a masked 10 g gluten challenge, the authors report that Nexvax2 did not reduce acute gluten-induced symptoms33.

A worked reading of one record

Take the latiglutenase gluten challenge study, record NCT0358547850. In order:

  1. Title and design. The record’s official title calls it a double-blind, placebo-controlled, gluten challenge trial of a 6-week treatment in well-controlled celiac disease50.
  2. Phase and status. Phase 2, Completed50. On its own, that does not tell you whether the drug worked.
  3. Enrollment. The record lists 79 participants (actual)50. The paper reports 50 randomized and 43 completing27. The two numbers differ, so say which one you are quoting.
  4. Results. No results are posted on the record50; they are in the paper, which gives the primary endpoint P value as .05727.
  5. Link between the two. The paper’s abstract names NCT03585478, which is how you connect a paper to its record28.

Candidates that stopped, and what is known about why

  • Larazotide acetate, Phase 3 (NCT03569007): Terminated; the reason field reads “Trial terminated by Sponsor”51.
  • Latiglutenase in symptomatic celiac disease (NCT04243551): Terminated; the reason given is low enrollment related to Covid49.
  • KAN-101 Phase 1b/2 (NCT05574010): Terminated; the reason given is “Sponsor decision”46.
  • Nexvax2: the paper reports that the study was discontinued after a planned interim analysis32 and that Nexvax2 did not reduce acute gluten-induced symptoms33.

A one-line reason field is not an explanation of why a drug stopped, and we do not guess beyond it.

How to check a headline that says “breakthrough” or “cure”

  1. Find the name or the NCT number. A headline with neither cannot be checked against a record.
  2. Read the phase. A Phase 2 study is not large enough, FDA says, to show whether a drug will be beneficial14.
  3. Read the design. Was there a control group, and was a gluten challenge part of the study? A result in people undergoing a challenge is a result about that design21.
  4. Read which endpoint was primary and which were secondary. In the AMG 714 trial the primary endpoint did not differ significantly from placebo, while the authors also point to effects on intraepithelial lymphocyte density and symptoms30.
  5. Read the status and last update date on the record, and whether results are posted or only in a paper.
  6. Look for “cure”. The 2025 review we read says no treatment had yet been conclusively proven an effective alternative to the gluten-free diet5.

Finding and screening a trial

NIDDK points readers to ClinicalTrials.gov, where a filtered list shows celiac studies that are federally funded, open and recruiting8. The list can be widened to include studies from industry, universities and individuals, which the NIH does not review9. NIDDK’s advice is to talk with your health care provider before taking part in any clinical study10.

In the UK, Coeliac UK lists taking part in a clinical trial as one way to take part in research36. On the day we read its page, it described one trial recruiting adults with coeliac disease who follow a gluten-free diet but still have symptoms37.

Eligibility is set by the study’s selection criteria19. The record shows some of them: the ZED1227 record, for example, lists an age range of 18 to 80 and Germany as its location38.

Questions the record may not answer

  • Will I receive placebo, and for how long?
  • Will the study ask me to eat gluten, how much, and for how many days?
  • Does it include a biopsy, and how many visits does it need?
  • Who is the sponsor, and who do I contact with questions or if I want to leave?

Questions people ask

Is there a vaccine for celiac disease?

Gluten Intolerance Group mentions the idea of a vaccine-based approach to prevent celiac disease developing4, and says nothing has proven effective yet among the drugs being studied3. A headline about a vaccine can be checked the same way as any other candidate: find its name or NCT number, then read the record.

Does a Completed trial mean the drug worked?

Not by itself. The AMG 714 gluten-challenge study is listed Completed48, and its paper reports that AMG 714 did not prevent mucosal injury due to gluten challenge53.

Why do celiac drug trials give volunteers gluten?

Some trials do it so they can measure whether a drug attenuates gluten-induced damage. For example, the ZED1227 trial measured attenuation of gluten-induced mucosal damage in adults on a daily gluten challenge21.

More in Gut science, healing and treatment research

Sources

  • [1] National Institute of Diabetes and Digestive and Kidney Diseases, Treatment for Celiac Disease, checked Nov 17, 2026.
  • [2, 3, 4] Gluten Intolerance Group, New and Emerging Celiac Research, checked Nov 17, 2026.
  • [5, 6] PubMed (Nutrients), Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments (Girbal-González and Pérez-Cano, 2025), checked Nov 17, 2026.
  • [7, 8, 9, 10] National Institute of Diabetes and Digestive and Kidney Diseases, Clinical Trials for Celiac Disease, checked Nov 17, 2026.
  • [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 54] US Food and Drug Administration, The Drug Development Process: Step 3, Clinical Research, checked Nov 17, 2026.

    Read on 2026-11-17: the page footer reads “Content current as of: 01/04/2018”.

  • [21, 22, 23, 24] PubMed (N Engl J Med), A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease (Schuppan et al., N Engl J Med 2021), checked Nov 17, 2026.
  • [25, 26, 27, 28] PubMed (Gastroenterology), Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge (Murray et al., Gastroenterology 2022), checked Nov 17, 2026.
  • [29, 30, 35, 53] PubMed (Lancet Gastroenterol Hepatol), AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a randomised placebo-controlled study (Lancet Gastroenterol Hepatol 2019), checked Nov 17, 2026.
  • [31, 32, 33, 34] PubMed (Lancet Gastroenterol Hepatol), Nexvax2 in adults with coeliac disease after bolus exposure to gluten (RESET CeD): interim analysis of a terminated phase 2 study (Tye-Din et al., Lancet Gastroenterol Hepatol 2023), checked Nov 17, 2026.
  • [36, 37] Coeliac UK, Research participation, checked Nov 17, 2026.
  • [38] ClinicalTrials.gov (US National Library of Medicine), Study record NCT07298343: ZED1227 in non-responsive celiac disease, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT07298343: phase Phase 2; overall status Recruiting; lead sponsor Dr. Falk Pharma GmbH; last update posted 2026-04-02; masking Double; enrollment 356 (estimated); interventions listed: ZED1227 + SIGE, Placebo; no results posted on the record. Locations listed include Germany; eligibility ages 18 to 80 years. Primary outcome measure listed: Change in CDSD GI Specific Symptom Score. Official title on the record: “A Phase II, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-free Diet”.

  • [39] ClinicalTrials.gov (US National Library of Medicine), Study record NCT07239336: DONQ52 in active celiac disease (DAISY), checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT07239336: phase Phase 2; overall status Recruiting; lead sponsor Chugai Pharmaceutical; last update posted 2026-08-14; masking Double; enrollment 92 (estimated); interventions listed: Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule; no results posted on the record. Primary outcome measure listed: Change in Villous Height to Crypt Depth Ratio (Vh:Cd).

  • [40] ClinicalTrials.gov (US National Library of Medicine), Study record NCT06982963: FB102 in adults on a gluten-free diet, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT06982963: phase Phase 2; overall status Recruiting; lead sponsor Forte Biosciences, Inc.; last update posted 2025-11-18; masking Quadruple; enrollment 100 (estimated); interventions listed: FB102, Placebo; no results posted on the record. Primary outcome measure listed: Change from baseline in the VCIEL.

  • [41] ClinicalTrials.gov (US National Library of Medicine), Study record NCT06807463: TEV-53408 during oral gluten exposure, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT06807463: phase Phase 2; overall status Active, not recruiting; lead sponsor Teva Branded Pharmaceutical Products R&D LLC; last update posted 2026-10-09; masking Double; enrollment 50 (actual); interventions listed: TEV-53408, Placebo; no results posted on the record. Primary outcome measure listed: Change From Baseline in Villous Atrophy as Measured by Villous Height to Crypt Depth Ratio (Vh:Cd); Number of Participants With at Least One Treatment-Emergent Adverse Event; Number of Participants With at Least One Treatment-Emergent Serious Adverse Event; Number of Participants With at Least One Protocol-Defined Adverse Event of Special Interest (PDAESI); Number of Participants Who Discontinued From the Study Due to an Adverse Event.

  • [42] ClinicalTrials.gov (US National Library of Medicine), Study record NCT06557772: Amlitelimab in non-responsive celiac disease, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT06557772: phase Phase 2; overall status Active, not recruiting; lead sponsor Sanofi; last update posted 2026-08-31; masking Quadruple; enrollment 229 (actual); interventions listed: Amlitelimab, Placebo, SIGE, Gluten-free product (GFP); no results posted on the record. Primary outcome measure listed: Change in Villus Height to Crypt Depth Ratio (Vh:Cd) from baseline to Week 28.

  • [43] ClinicalTrials.gov (US National Library of Medicine), Study record NCT05353985: TAK-062 in active celiac disease, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT05353985: phase Phase 2; overall status Completed; lead sponsor Takeda; last update posted 2025-08-20; masking Quadruple; enrollment 153 (actual); interventions listed: TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar; results posted on the record. Primary outcome measure listed: Change in Weekly Celiac Disease Symptom Diary (CDSD) Gastrointestinal (GI) Symptom Severity Score From Baseline to Week 12.

  • [44] ClinicalTrials.gov (US National Library of Medicine), Study record NCT04530123: TAK-101 dose-ranging, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT04530123: phase Phase 2; overall status Completed; lead sponsor Takeda; last update posted 2026-11-10; masking Triple; enrollment 102 (actual); interventions listed: Placebo, TAK-101, Gluten; results posted on the record. Primary outcome measure listed: Change From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) Assay.

  • [45] ClinicalTrials.gov (US National Library of Medicine), Study record NCT06001177: KAN-101 phase 2a, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT06001177: phase Phase 2; overall status Completed; lead sponsor Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA; last update posted 2025-12-18; masking Triple; enrollment 55 (actual); interventions listed: KAN-101, Placebo; results posted on the record. Primary outcome measure listed: Changes From Baseline in Villous Height to Crypt Depth (Vh:Cd) as Assessed by Esophagogastroduodenoscopy With Biopsy After 2-week Gluten Challenge (GC).

  • [46] ClinicalTrials.gov (US National Library of Medicine), Study record NCT05574010: KAN-101 phase 1b/2 (ACeD-it), checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT05574010: phase Phase 1/Phase 2; overall status Terminated; lead sponsor Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA; last update posted 2026-03-10; masking Triple; enrollment 128 (actual); interventions listed: Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C; results posted on the record. Reason given for stopping: “Sponsor decision” Primary outcome measure listed: Incidence and Severity of TEAEs as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) in Part A; Change in Pre- and Post-Gluten Challenge (GC) IL-2 Response From Baseline to Day 15; Change in IL-2 Response From Day 15 Pre-GC to Day 15 Post GC.

  • [47] ClinicalTrials.gov (US National Library of Medicine), Study record NCT04424927: PRV-015 in non-responsive celiac disease, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT04424927: phase Phase 2; overall status Completed; lead sponsor Provention Bio, a Sanofi Company; last update posted 2025-10-20; masking Quadruple; enrollment 388 (actual); interventions listed: PRV-015, Placebo; results posted on the record. Primary outcome measure listed: Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24.

  • [48] ClinicalTrials.gov (US National Library of Medicine), Study record NCT02637141: AMG 714 in adults with celiac disease, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT02637141: phase Phase 2; overall status Completed; lead sponsor Amgen; last update posted 2019-12-03; masking Quadruple; enrollment 64 (actual); interventions listed: AMG 714, Placebo, Placebo Gluten Challenge, Gluten Challenge; results posted on the record. Primary outcome measure listed: Percent Change From Baseline in Villous Height to Crypt Depth Ratio (VH:CD) at Week 12.

  • [49] ClinicalTrials.gov (US National Library of Medicine), Study record NCT04243551: Latiglutenase in symptomatic celiac disease (crossover), checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT04243551: phase Phase 2; overall status Terminated; lead sponsor Entero Therapeutics; last update posted 2024-08-05; masking Double; enrollment 83 (actual); interventions listed: Latiglutenase, Placebo; no results posted on the record. Reason given for stopping: “Due to low enrollment related to Covid.” Primary outcome measure listed: Symptom Severity Reduction.

  • [50] ClinicalTrials.gov (US National Library of Medicine), Study record NCT03585478: Latiglutenase gluten challenge trial, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT03585478: phase Phase 2; overall status Completed; lead sponsor Immunogenics, LLC; last update posted 2021-12-15; masking Triple; enrollment 79 (actual); interventions listed: Latiglutenase, Placebo; no results posted on the record. Primary outcome measure listed: Histologic Protection. The official title on the record describes a double-blind, placebo-controlled gluten challenge trial of a 6-week latiglutenase treatment in patients with well-controlled celiac disease.

  • [51] ClinicalTrials.gov (US National Library of Medicine), Study record NCT03569007: Larazotide acetate phase 3, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT03569007: phase Phase 3; overall status Terminated; lead sponsor 9 Meters Biopharma, Inc.; last update posted 2022-07-26; masking Triple; enrollment 307 (actual); interventions listed: Larazotide, Matching Placebo; no results posted on the record. Reason given for stopping: “Trial terminated by Sponsor” Primary outcome measure listed: Proportion of subjects who are binary responders.

  • [52] ClinicalTrials.gov (US National Library of Medicine), Study record NCT03644069: Nexvax2 phase 2, checked Nov 17, 2026.

    Read on 2026-11-17 from ClinicalTrials.gov's record data for NCT03644069: phase Phase 2; overall status Unknown status; lead sponsor ImmusanT, Inc.; last update posted 2019-03-19; masking Quadruple; enrollment 146 (estimated); interventions listed: Nexvax2, Placebo; no results posted on the record. Primary outcome measure listed: Efficacy of Nexvax2 compared to placebo in reducing Celiac Disease (CeD) associated GI symptoms.. Completion date on the record: 2019-09 (estimated).